More About The Christopher Klebanoff Lab Minus iconIcon indicating subtraction, or that the element can be closed. Plus IconIcon indicating addition, or that the element can be opened. Arrow (down) icon.An arrow icon, usually indicating that the containing element can be opened and closed.
  • The Christopher Klebanoff Lab
  • Projects Minus iconIcon indicating subtraction, or that the element can be closed. Plus IconIcon indicating addition, or that the element can be opened. Arrow (down) icon.An arrow icon, usually indicating that the containing element can be opened and closed.
  • Lab Members Minus iconIcon indicating subtraction, or that the element can be closed. Plus IconIcon indicating addition, or that the element can be opened. Arrow (down) icon.An arrow icon, usually indicating that the containing element can be opened and closed.
  • Former Lab Members Minus iconIcon indicating subtraction, or that the element can be closed. Plus IconIcon indicating addition, or that the element can be opened. Arrow (down) icon.An arrow icon, usually indicating that the containing element can be opened and closed.
  • Career Opportunities Minus iconIcon indicating subtraction, or that the element can be closed. Plus IconIcon indicating addition, or that the element can be opened. Arrow (down) icon.An arrow icon, usually indicating that the containing element can be opened and closed.
  • Publications

About Projects

The lab simultaneously pursues two complimentary research aims. The first is the discovery and clinical development of T cell receptors that confer specific recognition of cancer cells through the targeting of three classes of antigens: i) cancer germline antigens, ii) hotspot mutation-induced neoepitopes, and iii) private somatic mutations unique to each patient. Second, using a combination of genetic engineering, cellular isolation techniques, and pharmacologic disruption of key metabolic and signal transduction pathways, we aim to place anti-cancer receptors into optimal T cell subsets capable of long term persistence and sustained antitumor activity. The goal of the lab’s research is to extend the ability of adoptively transferred T cells to mediate curative responses beyond hematologic cancers and melanoma to common epithelial cancers, including breast cancer.